查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020118

產後憂鬱症治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Postpartum Depression Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

產後憂鬱症(PPD) 治療市場的成長要素

由於人們對產後憂鬱症（PPD）的認知不斷提高、盛行率不斷上升以及治療方法的進步，全球產後憂鬱症治療市場正在迅速擴張。預計到2025年，該市場規模將達到1.1483億美元，到2026年成長至1.6684億美元，到2034年將達到13.7985億美元，在預測期（2026-2034年）內，複合年成長率將高達30.22%。

產後憂鬱症是一種嚴重的疾病，會影響懷孕期間或產後一年內的女性。其特徵是持續的悲傷、焦慮和疲勞，全球約有10%至15%的女性受其影響。隨著人們對孕產婦心理健康的日益關注，對有效治療方法（包括藥物治療和心理諮商）的需求顯著增加。

市場動態

主要成長要素

市場成長的主要促進因素之一是全球產後憂鬱症盛行率的上升。除了診斷率的增加，宣傳宣傳活動的擴大也促使更多女性尋求治療。各國政府和醫療機構正積極透過各種措施和宣傳活動來促進孕產婦心理健康。

另一個主要因素是神經科學和藥物研究的進步。各公司正致力於開發創新藥物和治療方法。諸如祖拉諾酮等新藥的問世，拓寬了治療選擇，並提高了藥物的可及性。

此外，遺傳傾向、憂鬱症病史和社會經濟壓力等風險因素導致患者數量增加，進而推動了對治療方案的需求。

新冠疫情的影響

新冠疫情在2020年和2021年對市場造成了特別負面的影響。治療延誤、診斷率下降以及臨床試驗中斷都阻礙了市場成長。然而，隨著醫療服務的重新開放以及人們對心理健康的日益關注，市場在2022年和2023年開始復甦。

市場趨勢

塑造市場格局的關鍵趨勢之一是將人工智慧（AI）融入診斷和治療領域。研究人員正在開發人工智慧工具，以改善早期檢測和患者照護。數位平台和行動應用程式也日益普及，幫助醫護人員和患者更有效地管理症狀。

此外，對心理健康技術的投入增加以及創新診斷工具的開發，預計將在未來幾年加速市場成長。

細分分析

藥物

在市場區隔中，這些藥物被分為普瑞沙諾酮、祖拉諾酮和其他藥物。普瑞沙諾酮佔了主導市場佔有率，因為它是首個核准用於治療產後憂鬱症的藥物。

由於具有口服、成本低廉、使用方便等優勢，祖拉諾酮類藥物預計將呈現最高的成長率。該藥物於2023年核准，標誌著擴大治療可及性的一個重要里程碑。

透過行政途徑

根據給藥途徑，市場可分為口服、注射和其他途徑。口服給藥因其便利性、安全性和較高的患者接受度而佔市場主導地位。口服藥物的引入極大地提高了患者獲得治療的機會。

腸外給藥領域也佔了相當大的佔有率，這得益於其能夠提供快速的生理反應和持續的效果。

透過分銷管道

市場區隔將市場分為醫院藥局和專科藥局。由於住院患者數量的增加和處方箋治療的擴展，醫院藥房佔市場主導地位。

隨著各公司與分銷合作夥伴合作，將藥物直接送到患者手中，專業藥房的發展勢頭日益強勁，從而提高了藥物的可及性和用藥依從性。

區域趨勢

北美在產後憂鬱症治療市場佔主導地位，預計2025年將佔全球市場佔有率的97.93%，市場規模達到1.1244億美元。在較高的認知度、先進的醫療基礎設施和強力的監管支持的推動下，該地區預計到2026年市場規模將達到1.6303億美元。

亞太地區是一個新興市場，預計2025年市場規模為238萬美元，2026年為381萬美元。該地區的成長是由人們意識的提高、醫療保健投資的增加以及對孕產婦健康日益成長的興趣所推動的。

包括歐洲和拉丁美洲在內的其他地區，由於政府主導的舉措和人們對心理健康護理日益成長的興趣，也出現了逐步成長。

策略聯盟、產品核准和研發投資仍是市場參與企業鞏固自身地位的關鍵策略。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025/2025年主要國家及地區產後憂鬱症盛行率
  • 主要企業管道分析
  • 主要國家/地區的法規和還款狀況
  • 產業重大發展動態：併購與合作
  • 新冠疫情對全球產後憂鬱症市場的影響

第5章：2021-2034年全球產後憂鬱症治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物分類
    • 祖拉諾隆
    • 布瑞沙諾酮
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 專科藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 亞太地區
    • 世界其他地區

第6章：北美產後憂鬱症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：亞太地區產後憂鬱症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他亞太國家

第8章：2021-2034年全球產後憂鬱症治療市場分析、洞察與預測

第9章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Sage Therapeutics, Inc.
    • Biogen Inc.
    • Brii Biosciences Limited
    • GH Research Ireland Limited
Product Code: FBI109264

Growth Factors of postpartum depression (PPD) treatment Market

The global postpartum depression (PPD) treatment market is experiencing rapid expansion due to increasing awareness, rising prevalence, and advancements in treatment options. The market was valued at USD 114.83 million in 2025 and is projected to grow to USD 166.84 million in 2026, reaching USD 1,379.85 million by 2034, exhibiting a remarkable CAGR of 30.22% during the forecast period (2026-2034).

Postpartum depression is a serious medical condition affecting women during pregnancy or within the first year after childbirth. It is characterized by prolonged sadness, anxiety, and fatigue, impacting nearly 10% to 15% of women globally. The growing recognition of maternal mental health has significantly increased demand for effective treatment solutions, including medications and counseling.

Market Dynamics

Key Growth Drivers

One of the primary drivers of market growth is the increasing prevalence of postpartum depression worldwide. Rising diagnosis rates, coupled with growing awareness campaigns, are encouraging more women to seek treatment. Governments and healthcare organizations are actively promoting maternal mental health through initiatives and awareness programs.

Another major factor is the advancement in neuroscience and pharmaceutical research. Companies are focusing on developing innovative drugs and therapies. The introduction of new medications, such as zuranolone, has expanded treatment options and improved accessibility.

Additionally, risk factors such as genetic predisposition, history of depression, and socio-economic stress are contributing to the growing patient population, thereby driving demand for therapeutic solutions.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the market, particularly in 2020 and 2021. Delays in treatment, reduced diagnosis rates, and disruptions in clinical trials hindered growth. However, the market began recovering in 2022 and 2023 due to the resumption of healthcare services and increased focus on mental health.

Market Trends

A key trend shaping the market is the integration of artificial intelligence (AI) in diagnosis and treatment. Researchers are developing AI-based tools to improve early detection and patient care. Digital platforms and mobile applications are also gaining traction, helping healthcare providers and patients manage symptoms more effectively.

Furthermore, increased funding for mental health technologies and the development of innovative diagnostic tools are expected to accelerate market growth in the coming years.

Segmentation Analysis

By Drug

The market is segmented into brexanolone, zuranolone, and others. The brexanolone segment holds a dominant share as it was the first FDA-approved drug for postpartum depression.

The zuranolone segment is expected to grow at the fastest rate due to its advantages, including oral administration, lower cost, and ease of use. Its approval in 2023 marked a significant milestone in expanding treatment accessibility.

By Route of Administration

Based on administration, the market includes oral, parenteral, and others. The oral segment dominates due to convenience, safety, and higher patient acceptance. The introduction of oral drugs has revolutionized treatment accessibility.

The parenteral segment also holds a significant share, driven by its ability to provide rapid physiological response and long-lasting effects.

By Distribution Channel

The market is segmented into hospital pharmacies and specialty pharmacies. Hospital pharmacies lead the market due to increased hospitalization and prescription-based treatments.

Specialty pharmacies are gaining traction as companies collaborate with distribution partners to deliver medications directly to patients, improving accessibility and adherence.

Regional Insights

North America dominates the postpartum depression treatment market, accounting for 97.93% of the global share in 2025, with a market size of USD 112.44 million. The region is projected to reach USD 163.03 million in 2026, driven by high awareness, advanced healthcare infrastructure, and strong regulatory support.

Asia Pacific is an emerging market, valued at USD 2.38 million in 2025 and expected to reach USD 3.81 million in 2026. Growth in this region is attributed to increasing awareness, rising healthcare investments, and growing focus on maternal health.

Other regions, including Europe and Latin America, are also witnessing gradual growth due to government initiatives and increasing attention to mental health care.

Competitive Landscape

The market is highly consolidated, with key players such as Sage Therapeutics, Inc. and Biogen Inc. leading the industry. These companies are actively involved in drug development and commercialization of innovative therapies.

Emerging players such as Brii Biosciences Limited and GH Research Ireland Limited are also contributing through clinical trials and pipeline products, intensifying competition in the market.

Strategic partnerships, product approvals, and research investments remain key strategies adopted by market participants to strengthen their positions.

Conclusion

The postpartum depression treatment market is set for exponential growth, expanding from USD 114.83 million in 2025 to USD 1,379.85 million by 2034. This growth is driven by increasing awareness, rising disease prevalence, and continuous advancements in treatment technologies. While high treatment costs and limited drug availability pose challenges, ongoing innovation and supportive healthcare initiatives are expected to unlock significant opportunities. Overall, the market will play a critical role in improving maternal mental health outcomes globally in the coming years.

Segmentation By Drug

  • Zuranolone
  • Brexanolone
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies

By Region

  • North America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • U.S.
    • Canada
  • Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of the Asia Pacific
  • Rest of the World ( By Drug, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Postpartum Depression - By Key Countries/Regions, 2025/2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Regulatory and Reimbursement Scenario, By Key Countries/Regions
  • 4.4. Key Industry Developments: Mergers, Acquisitions, and Partnerships
  • 4.5. Impact of COVID-19 on the Global Postpartum Depression Market

5. Global Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Zuranolone
    • 5.1.2. Brexanolone
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Specialty Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Asia Pacific
    • 5.4.3. Rest of the World

6. North America Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Zuranolone
    • 6.1.2. Brexanolone
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Specialty Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Asia Pacific Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Zuranolone
    • 7.1.2. Brexanolone
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Specialty Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. India
    • 7.4.4. Australia
    • 7.4.5. Rest of Asia Pacific

8. Rest of the World Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Zuranolone
    • 8.1.2. Brexanolone
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Specialty Pharmacies

9. Competitive Analysis

  • 9.1. Global Market Share Analysis (2025)
  • 9.2. Company Profiles
    • 9.2.1. Sage Therapeutics, Inc.
      • 9.2.1.1. Overview
      • 9.2.1.2. Products & Services
      • 9.2.1.3. SWOT Analysis
      • 9.2.1.4. Recent Developments
      • 9.2.1.5. Strategies
      • 9.2.1.6. Financials (Based on Availability)
    • 9.2.2. Biogen Inc.
      • 9.2.2.1. Overview
      • 9.2.2.2. Products & Services
      • 9.2.2.3. SWOT Analysis
      • 9.2.2.4. Recent Developments
      • 9.2.2.5. Strategies
      • 9.2.2.6. Financials (Based on Availability)
    • 9.2.3. Brii Biosciences Limited
      • 9.2.3.1. Overview
      • 9.2.3.2. Products & Services
      • 9.2.3.3. SWOT Analysis
      • 9.2.3.4. Recent Developments
      • 9.2.3.5. Strategies
      • 9.2.3.6. Financials (Based on Availability)
    • 9.2.4. GH Research Ireland Limited
      • 9.2.4.1. Overview
      • 9.2.4.2. Products & Services
      • 9.2.4.3. SWOT Analysis
      • 9.2.4.4. Recent Developments
      • 9.2.4.5. Strategies
      • 9.2.4.6. Financials (Based on Availability)

List of Tables

  • Table 1:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 2:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 3:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 4:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Region, 2021-2034
  • Table 5:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 6:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 7:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 8:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 10:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 11:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 12:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13:Rest of the World Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 14:Rest of the World Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 15:Rest of the World Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

List of Figures

  • Figure 1:Global Postpartum Depression Treatment Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034
  • Figure 2:Global Postpartum Depression Treatment Market Value Share (%), By Drug, 2025 & 2034
  • Figure 3:Global Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 4:Global Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 5:Global Postpartum Depression Treatment Market Value (USD million), By Region, 2025 & 2034
  • Figure 6:North America Postpartum Depression Treatment Market Value (USD million), By Drug, 2025 & 2034
  • Figure 7:North America Postpartum Depression Treatment Market Value Share (%), By Drug, 2025
  • Figure 8:North America Postpartum Depression Treatment Market Value (USD million), Route of Administration, 2025 & 2034
  • Figure 9:North America Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 10:North America Postpartum Depression Treatment Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 11:North America Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 12:North America Postpartum Depression Treatment Market Value (USD million), By Country, 2025 & 2034
  • Figure 13:North America Postpartum Depression Treatment Market Value Share (%), By Country, 2025
  • Figure 14:Asia Pacific Postpartum Depression Treatment Market Value (USD million), By Drug, 2025 & 2034
  • Figure 15:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Drug, 2025
  • Figure 16:Asia Pacific Postpartum Depression Treatment Market Value (USD million), Route of Administration, 2025 & 2034
  • Figure 17:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 18:Asia Pacific Postpartum Depression Treatment Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 19:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 20:Asia Pacific Postpartum Depression Treatment Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 21:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22:Rest of the World Postpartum Depression Treatment Market Value (USD million), By Drug, 2025 & 2034
  • Figure 23:Rest of the World Postpartum Depression Treatment Market Value Share (%), By Drug, 2025
  • Figure 24:Rest of the World Postpartum Depression Treatment Market Value (USD million), By Route of Administration, 2025 & 2034
  • Figure 25:Rest of the World Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 26:Rest of the World Postpartum Depression Treatment Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 27:Rest of the World Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 28:Global Postpartum Depression Treatment Market Share (%), By Company, 2025